Parkinson ‘s disease

Forging the Future of Cell Therapy: Bayer and BlueRock’s Unique Journey

4 days ago talkbio0Tagged Bayer, bemdaneprocel, biotech partnerships, BlueRock Therapeutics, Cell Therapy, Identifier, Parkinson 's disease, Phase 3 trials, Regenerative Medicine, RMAT

cell therapy; Bayer; BlueRock Therapeutics; Parkinson’s disease; bemdaneprocel; biotech partnerships; RMAT designation; Phase 3 trials; regenerative medicine

MeiraGTx and Hologen AI Form $430M Collaboration to Advance Parkinson’s Gene Therapy

3 months ago talkbio0Tagged Artificial Intelligence, Biotechnology, Clinical Trials, gene therapy, Parkinson 's disease

gene therapy, Parkinson’s disease, artificial intelligence, clinical trials, biotechnology partnership

FDA Approves Onapgo: Breakthrough Infusion Device for Advanced Parkinson’s Disease

4 months ago talkbio0Tagged apomorphine hydrochloride, Approved, Infusion procedures, motor fluctuations, Onapgo, Parkinson 's disease, subcutaneous, Supernus, United States Food and Drug Administration

Onapgo, apomorphine hydrochloride, Parkinson’s disease, subcutaneous infusion, motor fluctuations, FDA approval, Supernus Pharmaceuticals

Inhibikase Halts Parkinson’s Drug Development After Phase II Failure, Shifts Focus to Pulmonary Arterial Hypertension

4 months ago talkbio0Tagged Clinical Failure, Drug Development, IkT-001Pro, Inhibikase, Parkinson 's disease, Phase 2 Clinical Trials, Pulmonary arterial hypertension, risvodetinib

Inhibikase Therapeutics, risvodetinib, Parkinson’s disease, Phase II trial, clinical failure, drug development, pulmonary arterial hypertension (PAH), IkT-001Pro

Medtronic Launches Adaptive Brain Stimulation for Parkinson’s Disease Following EU Approval

5 months ago talkbio0Tagged adaptive, Approved, BrainSense, CE (Rh group), Deep Brain Stimulation, EU, Massive, Medtronic, Parkinson 's disease

Medtronic, BrainSense, Adaptive Deep Brain Stimulation, Parkinson’s Disease, EU Approval, CE Mark

Roche’s Prasinezumab Fails Primary Endpoint in Phase 2b Parkinson’s Trial, Shows Promising Trends

6 months ago talkbio0Tagged alpha-Synuclein, PADOVA study, Parkinson 's disease, Phase 2b Trial, Prasinezumab, Prothena, Roche (company)

Roche, Prothena, Parkinson’s disease, prasinezumab, alpha-synuclein, phase 2b trial, PADOVA study

Roche’s Parkinson’s Drug Fails Second Mid-Stage Trial, Yet Shows Promising Trends

6 months ago talkbio0Tagged Clinical Trials, exploration, Failure (biologic function), Parkinson 's disease, Prasinezumab, Roche (company), trends qualifier

Roche, Parkinson’s disease, prasinezumab, clinical trial failure, promising trends, further exploration

UCB and Novartis Discontinue Development of Parkinson’s Disease Drug After Phase 2 Failure

6 months ago talkbio0Tagged Drug Development, Novartis, Parkinson 's disease, Phase 2 Failure, UCB

UCB, Novartis, Parkinson’s disease, drug development, Phase 2 failure, UCB0599, UCB7853

GSK Enters Strategic Alliance with Vesalius Therapeutics for Parkinson’s Disease Treatments

7 months ago talkbio0Tagged Neurodegenerative Disorders, Parkinson 's disease, SmithKline Beecham, Strategic Alliance, Vesalius

GSK, Vesalius Therapeutics, Parkinson’s disease, neurodegenerative diseases, strategic alliance, small molecule program

MeiraGTx’s Gene Therapy Shows Significant Improvements in Motor Function and Quality of Life in Parkinson’s Disease Trial

8 months ago talkbio0Tagged AAV-GAD, Clinical Trials, dopamine, gamma-aminobutyric acid, gene therapy, MeiraGTx, Motor function (observable entity), Neurodegenerative Disorders, Parkinson 's disease, Phase 2 trial, production, Quality of life, Surgical Replantation

MeiraGTx, Gene Therapy, Parkinson’s Disease, AAV-GAD, Motor Function, Quality of Life, Clinical Trial, Phase 2 Trial, Neurodegenerative Disease, Dopamine Replacement, GABA Production